Enliven Therapeutics: Collins exercises 5,000 options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Enliven Therapeutics, Inc. Chief Medical Officer Helen Louise Collins exercised options to acquire 5,000 common shares at $2.48 per share on November 17, 2026. The reported option position after the exercise was 96,268 shares. Collins also sold 4,939 common shares at a weighted average $46.8313 per share and 61 RSU shares at a weighted average $47.5954 per share that day.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F6 | 5,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 5,000 | $2.48 | $12K |
| Sale | Common Stock F1, F3, F2 | 4,939 | $46.8313 | $231K |
| Sale | Common Stock F1, F4, F5 | 61 | $47.5954 | $3K |
Footnotes (6)
- F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
- F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- F3. This transaction was executed in multiple trades at prices ranging from $46.455 to $47.435. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4. This transaction was executed in multiple trades at prices ranging from $47.5074 to $47.745. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- F6. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
restricted stock units (RSUs) financial
weighted average sale price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did Enliven Therapeutics (ELVN) Chief Medical Officer Helen Louise Collins exercise?
AI-generated analysis. How Rhea-AI works. Not financial advice.